n randomized controlled trials sirolimus-eluting stents (SES) have been shown to reduce the incidence of restenosis and revascularization compared with baremetal stents (BMS). 1,2 However, there is a small but sizable number of patients who develop restenosis following SES implantation and several factors, such as diabetes, renal insufficiency, and long lesion length, have been identified as predictors of restenosis and revascularization, 3,4 which is similar to BMS implantation. Although Koster et al reported that metallic allergy was frequently observed in patients with BMS restenosis compared with patients without restenosis, 5 the impact of metallic allergy on the outcome after implantation of drug-eluting stents (DES) has not been investigated. The aim of this study was to investigate the relationship between metallic allergies and angiographic outcomes after SES implantation.
within 3 months requiring withdrawal of antiplatelet therapy, endstage renal disease on dialysis, or inappropriate vessel size for SES were excluded. In our protocol, follow-up angiography was routinely performed at 8 months, except for those patients with contraindications or high risks for angiography. 3 At the time of follow-up angiography, the patients underwent epicutaneous patch tests using Finn chamber on Scanpor tape with the following materials, which are the main components of 316 L stainless steel (used as the platform of SES): nickel sulfate (5.0%), potassium chromate (0.4%), molybdenum (20%) in petrolatum, manganese chloride (2.0%) in petrolatum, and titanium (20%) in petrolatum. Patch tests were evaluated as described previously. 6 In brief, Finn chambers were removed at 48 h and the reaction was evaluated. A positive reaction was defined as an inflammatory response with erythema, edema, or papulovesicles. Written informed consent was given by all patients. Coronary angiograms obtained at baseline, postprocedure, and at 8 months follow-up were analyzed by a computer-based system (CMS version 6.0, Medis Medical Imaging Systems, Nuenen, The Netherlands). Three coronary segments (in-stent, proximal edge, and distal edge segment) were analyzed by quantitative coronary angiography (QCA). The proximal and distal edge segments included up to 5 mm on either side of the in-stent segment.
Pre-dilatation and post-dilatation were allowed according to the operator's decision.
Definitions
The number of diseased vessels was defined as the number of major coronary arteries with luminal diameter stenosis ≥50%. Binary restenosis was defined as stenosis >50% of the luminal diameter in the target lesion. Late lumen loss was defined as the difference between the minimal lumen diameter (MLD) at the completion of the stenting procedure and the same measured at follow-up.
Statistical Analysis
Continuous variables are expressed as mean ± standard deviation (SD). Comparisons between 2 groups were performed by Student's t-test for independent samples and using the chi-square test for categorical values. Wilcoxon's test was used for the analysis of abnormally distributed parameters. All analyses were performed using SPSS software (SPSS for Windows version 11.5, Chicago, IL, USA). A p-value <0.05 was considered statistically significant.
Results

Patch Tests and Baseline Patient and Lesion Characteristics
Positive patch tests were documented in 14 of 88 patients (16%): 9 patients had a positive patch test for only 1 substance (5 for manganese, 3 for nickel, and 1 for chromate), and 5 patient showed a positive patch test for 2 substances (1 for nickel + manganese, and 4 for manganese + chromate). None of the patients had a systemic reaction.
The baseline patient and lesion characteristics are shown in Tables 1 and 2 . The prevalence of women was significantly higher in the positive patch test group, whereas hypertensive patients were more frequently found in the negative patch test group. Lesion characteristics were comparable between the 2 groups, except for the higher prevalence of LAD lesions in the positive patch test group.
Clinical and Angiographic Outcomes
Neither death nor MI was reported in any of the patients. Target lesion revascularization was performed in 6 (8%) 
Discussion
In the present study, we demonstrated that SES suppressed neointimal growth despite the presence of metallic allergy. It is known that direct contact with stainless steel can cause an allergic reaction. 7, 8 Koster et al found metallic allergy in 10% of patients following stent implantation. 5 In the present study, there was a slightly higher incidence of positive patch test (16%), which might be related to a high prevalence of prior PCI. We have previously reported that recurrent BMS restenosis is related to metallic allergy, 6 and in the current study, there was similar prevalence of BMS restenosis lesion between the patch test positive and negative group [ Interestingly, none of the 3 cases with BMS restenosis lesion in the positive patch test group showed recurrent restenosis, although they were considered to be at high risk of restenosis. 6 Local exposure to stainless steel, which contains nickel, chromate, manganese, and molybdenum, causes type IV hypersensitivity mediated by allergen-specific T lymphocytes. A previous report described a patient with metallic allergy showing aseptic loosening of an orthopedic chromium/cobalt alloy and T-lymphocyte infiltrate was documented around the tissue. 9 Similarly, inflammatory cells including T lymphocytes were seen around the stent struts at a site of restenosis following PCI that was considered to be caused by a foreign body reaction. 10 11 Local delivery of sirolimus has shown potent anti-proliferative effects following stent implantation and has achieved clinical success in preventing restenosis. 1,2 Sirolimus binds to the immunophilin FK506 binding protein-12 (FKBP-12) and this complex inhibits the kinase activity of the mammalian target of rapamycin. Subsequently, the pathway leads to cell cycle arrest at the G1/S transition point by reducing cell-cycle kinase activity 12 and inhibits vascular smooth muscle cell proliferation. However, the sirolimus/FKBP-12 complex also inhibits interleukin-2-driven T-lymphocyte proliferation, which is the main mechanism of immunosuppression in organ transplantation. 13 It is likely that these properties of sirolimus suppress the hypersensitivity reaction induced by metallic allergy after stent implantation. As a result, SES reduce the rates of restenosis and neointimal growth in patients with metallic allergy.
However, a hypersensitivity reaction has been documented in patients following SES implantation. Virmani et al described a case of very late stent thrombosis caused by hypersensitivity reaction at 18 months post implantation. 14 Autopsy showed aneurysmal dilation of the stented artery and severe hypersensitivity reaction consisting of T lymphocytes and eosinophils. Because sirolimus loading on the stent should have been completely released by this time, a non-erodable polymer was considered to be the cause of this reaction. Recently, larger data sets from the Research on Adverse Drug/Device Events and Reports identified 17 hypersensitivity cases associated with implantation of DES. 15 Those cases were associated with a high mortality rate and/or other serious clinical events. The sequelae of hypersensitivity reactions with DES are different from those seen with BMS, which is the main stent type associated with restenosis. We only investigated metallic allergy after SES implantation in the present study and it may be important to investigate the association between contact allergies to polymer and the clinical events after SES implantation.
Patch negative
Study Limitations
Our data were obtained from a small sample size in a single center. In addition, we have reported clinical and angiographic outcomes only at 8 months following PCI, which may not be sufficiently long, because late DES thrombosis has emerged as a concern 16, 17 and a slight increase in neointimal volume beyond 1 year following DES implantation also has been reported. 18 The mechanism of these consequences is not fully understood. Therefore, our findings should be confirmed by a study with a larger sample size and longer follow-up.
Conclusion
SES prevent restenosis, irrespective of metallic allergy. The classic relationship between metallic allergy and instent restenosis, seen with BMS, does not appear to arise with SES, possibly because of the immunosuppressive effect of sirolimus.
